中
繁
EN
Search form
Search this site
Home
About Us
Our Story
Leadership
Board of Directors
Jacobio people stories
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
For Patients
Investors
Careers
Contact
Company News
84
press releases in total
Year
-Year
2026
2025
2024
2023
2022
2021
2020
2019
2018
2023
Oct 27, 2023
Jacobio Completes First Patient Dosage of Glecirasib in a Pivotal Clinical Trial for the Treatment of Pancreatic Cancer in China
[More]
Oct 22, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO
[More]
Aug 30, 2023
Jacobio Pharma Announces 2023 Interim Results
[More]
Aug 7, 2023
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer
[More]
Jul 21, 2023
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference
[More]
Jul 4, 2023
Jacobio Receives CDE Approval for Glecirasib’s Pancreatic Cancer Pivotal Study in China
[More]
Jun 29, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer
[More]
Jun 8, 2023
Jacobio Pharma Receives IND Approval for PARP7 Inhibitor JAB-26766 in China
[More]
Apr 18, 2023
Jacobio Pharma Presented Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
[More]
Apr 4, 2023
Jacobio Pharma Receives IND Approval for LIF mAb JAB-BX300 in China
[More]
Mar 22, 2023
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
[More]
Mar 22, 2023
Jacobio Pharma Announces 2022 Annual Results
[More]
Mar 17, 2023
Jacobio Receives IND Approval for GUE Inhibitor JAB-24114 in China
[More]
Mar 15, 2023
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
[More]
Jan 8, 2023
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S.
[More]
2022
Dec 16, 2022
Jacobio’s KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
[More]
Dec 2, 2022
Jacobio’s Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
[More]
Oct 29, 2022
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 in China
[More]
Oct 13, 2022
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab
[More]
Sep 16, 2022
Jacobio Completes First Patient Dosage of JAB-21822’s Phase II Pivotal Study in China
[More]
Pages
«
‹
1
2
3
4
5
›
»
京公网安备 11030102011242号